For research use only. Not for therapeutic Use.
Deserpidine (INN) is an antihypertensive drug related to reserpine which occurs naturally in Rauwolfia canescens. Deserpidine is a competitive inhibitor of the angiotensin converting enzyme (ACE). By competing with angiotensin I for ACE, deserpidine blocks the conversion of angiotensin I to angiotensin II, which is a potent vasoconstrictor. Reduced level of serum angiotensin II causes a decrease in blood pressure. Deserpidine also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex. (Source: https://en.wikipedia.org/wiki/Deserpidine).
| Catalog Number | R023620 |
| CAS Number | 131-01-1 |
| Synonyms | (3β,16β,17α,18β,20α)-17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic Acid Methyl Ester; Deserpidic Acid Methyl Ester 3,4,5-Trimethoxybenzoate; Deserpidin; 1-Demethoxyreserpine; 11-Desmethoxyreserpine; Canescin; Canescine; Canescine |
| Molecular Formula | C32H38N2O8 |
| Purity | ≥95% |
| Target | Angiotensin-converting Enzyme (ACE) |
| Storage | -20°C |
| IUPAC Name | methyl (1R,15S,17R,18R,19S,20S)-18-methoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate |
| InChI | InChI=1S/C32H38N2O8/c1-37-24-12-17(13-25(38-2)29(24)39-3)31(35)42-26-14-18-16-34-11-10-20-19-8-6-7-9-22(19)33-28(20)23(34)15-21(18)27(30(26)40-4)32(36)41-5/h6-9,12-13,18,21,23,26-27,30,33H,10-11,14-16H2,1-5H3/t18-,21+,23-,26-,27+,30+/m1/s1 |
| InChIKey | CVBMAZKKCSYWQR-WCGOZPBSSA-N |
| SMILES | COC1C(CC2CN3CCC4=C(C3CC2C1C(=O)OC)NC5=CC=CC=C45)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC |
| Reference | </br>1:Liquid chromatography/tandem mass spectrometry method for the quantification of deserpidine in human plasma: Application to a pharmacokinetic study. Zhang H, Zhong D, Zhang Z, Dai X, Chen X.J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Oct 1;877(27):3221-5. doi: 10.1016/j.jchromb.2009.06.005. Epub 2009 Jun 10. PMID: 19620026 </br>2:Synthesis of deserpidine from reserpine. Varchi G, Battaglia A, Samorì C, Baldelli E, Danieli B, Fontana G, Guerrini A, Bombardelli E.J Nat Prod. 2005 Nov;68(11):1629-31. PMID: 16309312 </br>3:Comparison of the effectiveness of deserpidine, reserpine, and alpha-methyltyrosine on brain biogenic amines. Fulton SC, Healy MD.Fed Proc. 1976 Dec;35(14):2558-62. No abstract available. PMID: 11134 </br>4:Deserpidine antagonism by a tripeptide, L-prolyl-L-leucyglycinamide. Plotnikoff NP, Kastin AJ, Anderson MS, Schally AV.Neuroendocrinology. 1973;11(1):67-71. No abstract available. PMID: 4633626 </br>5:Effect of deserpidine and pargyline on the levels of biogenic amines in brain, liver and heart of mice. Everett GM, Borcherding J, Morse P.Res Commun Chem Pathol Pharmacol. 1972 Mar;3(2):245-8. No abstract available. PMID: 4679851 </br>6:[Clinical laboratory study of essential hypertension patients treated with a methylclothiazide deserpidine combination]. da Rocha AL, Saldanha RV.Hospital (Rio J). 1968 Oct;74(4):1299-304. Portuguese. No abstract available. PMID: 5304160 </br>7:Pargyline hydrochloride, methyclothiazide, and deserpidine in therapy of hypertension and prevention of /cheese reaction/. Hutchison JC.Curr Ther Res Clin Exp. 1968 Mar;10(3):128-35. No abstract available. PMID: 4967000 </br>8:Clinical and laboratory observations on the use of a combination of methyclothiazide and deserpidine in treatment of essential hypertension. Shafei AZ, Abaza HH.J Egypt Med Assoc. 1968;51(1):48-56. No abstract available. PMID: 4876817 </br>9:The acid catalysed C3 epimerization of reserpine and deserpidine. Gaskell AJ, Joule JA.Tetrahedron. 1967 Oct;23(10):4053-63. No abstract available. PMID: 6065625 </br>10:[Treatment of essential arterial hypertension by the methyclothiazide-deserpidine]. de Faria CV.Rev Bras Med. 1967 May;24(5):331-3. Portuguese. No abstract available. PMID: 5603874 |
